Circulating markers of inflammation and atherosclerosis

Atherosclerosis

Volumn 169, Issue 2, 2003, Pages 203-214

  Lind, Lars ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Atherosclerosis; Circulating markers; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; NEOPTERIN; PHOSPHOLIPASE A2; SERUM AMYLOID A; SOLUBLE INTERLEUKIN 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE HEART FAILURE; ARTERY DISEASE; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; FIBRINOGEN BLOOD LEVEL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LEUKOCYTE COUNT; MACROPHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; STABLE ANGINA PECTORIS; STROKE;

EID: 0142061128     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00012-1     Document Type: Article

References (183)

1. Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med. 340:1999;115-126.
2. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
3. Schwartz C.J., Mitchell J.R.A. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation. 26:1962;73-78.
4. Kaartinen M., Pentilää A., Kovanen P.T. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 90:1994;1669-1678.
5. Falk K.E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br. Heart J. 50:1983;127-134.
6. Lendon C.L., Davies M.J., Born G.V.R., et al. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 87:1991;87-90.
7. van der Wal A.C., Becker A.E., van der Loos C.M., et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
8. Moreno P.R., Falk E., Palacios I.F., et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 90:1994;775-778.
9. Matrisian L.M. The matrix degrading metalloproteinases. Bioessays. 14:1992;455-463.
10. Rennick R.E., Ling K.L.E., Humphries S.E., et al. Effect of acetyl-LDL on monocyte/macrophage expression of matrix metalloproteinases. Atherosclerosis. 109:1994;192.
11. Casscells W., Hathorn B., David M., et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet. 347:1996;1447-1451.
12. Stefanadis C., Diamantopoulos L., Vlachopoulos C., et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. Circulation. 99:1999;1965-1971.
13. Cook D.G., Mendall M.A., Whincup P.H., et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atheroclerosis. 149:2000;139-150.
14. Mendall M.A., Patel P., Ballam L., et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br. Med. J. 312:1996;1061-1065.
15. Margaglione M., Cappucci G., Colaizzo D., et al. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler. Thromb. Vasc. Biol. 20:2000;198-203.
16. Stefanadis C., Diamantopoulos L., Dernellis J., et al. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J. Mol. Cell. Cardiol. 32:2000;43-52.
17. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 8:1990;253-278.
18. Papanicolaou D.A., Wilder R.L., Manolagas S.C., et al. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128:1998;127-137.
19. Baumann H., Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol. Biol. Med. 7:1990;147-159.
20. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265:1990;621-636.
21. Munro J.M., Cotran R.S. Biology of disease: the pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab. Invest. 58:1988;249-261.
22. Albelda S.M., Smith C.W., Ward P.A. Adhesion molecules and inflammatory injury. FASEB J. 8:1994;504-512.
23. O'Brien K.D., McDonald T.O., Chait A., et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 93:1996;672-682.
24. Libby P., Li H. Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J. Clin. Invest. 92:1993;538-539.
25. Alon R., Kassner P.D., Carr M.W., et al. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J. Cell Biol. 128:1995;1243-1253.
26. Berlin C., Bargatze R.F., Campell J.J. Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell. 80:1995;413-422.
27. Gerszten R.E., Luscinskas F.W., Ding H.T. Adhesion of memory lymphocytes to vascular cell adhesion molecule-1-transduced human vascular endothelial cells under simulated physiological flow conditions in vitro. Circ. Res. 79:1996;1205-1215.
28. Luscinskas F.W., Kansas G.S., Ding H., et al. Moncyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta 1-integrins, and beta 2-integrins. J. Cell Biol. 125:1994;1417-1427.
29. Schmidt A.M., Hori O., Chen J.X., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96:1995;1395-1403.
30. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl. J. Med. 342:2000;836-843.
31. Gram J., Bladbjerg E.M., Moller L., et al. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J. Intern. Med. 247:2000;205-212.
32. Jager A., van Hinsbergh V.W., Kostene P.J., et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler. Thromb. Vasc. Biol. 19:1999;3071-3078.
33. Koenig W., Sund M., Frolich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242.
34. Kuller T.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 144:1996;537-547.
35. Harris T.B., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106:1999;506-512.
36. Strandberg T.E., Tilvis R.S. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler. Thromb. Vasc. Biol. 20:2000;1057-1060.
37. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler. Thromb. Vasc. Biol. 17:1997;1121-1127.
38. Jager A., van Hinsbergh V.W., Kostense P.J., et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn Study. Diabetes. 49:2000;485-491.
39. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl. J. Med. 336:1997;973-979.
40. Ridker P.M., Buring J.E., Shih J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98:1998;731-733.
41. Kannel W.B., Anderson K., Wilson P.W. White blood cell count and cardiovascular disease. Insights from the Framingham Study. J. Am. Med. Assoc. 267:1992;1253-1256.
42. Weijenberg M.P., Feskens E.J., Kromhout D. White blood cell count and the risk of coronary heart disease and all-cause mortality in elderly men. Arterioscler. Thromb. Vasc. Biol. 16:1996;499-503.
43. Manttari M., Manninen V., Koskinen P., et al. Leukocytes as a coronary risk factor in dyslipidemic male population. Am. Heart J. 123:1992;873-877.
44. Folsom A.R., Wu K.K., Rosamond W.D., et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 96:1997;1102-1108.
45. Gillum R.F., Ingram D.D., Makue D.M. White blood cell count, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am. Heart J. 125:1993;855-863.
46. Philips A.N., Neaton J.D., Cook D.G., et al. Leukocyte count and risk of major coronary heart disease events. Am. J. Epidemiol. 136:1992;59-70.
47. Olivares R., Ducimetiere P., Claude J.R. Monocyte count: a risk factor for coronary heart disease. Am. J. Epidemiol. 137:1993;49-53.
48. Sweetnam P.M., Thomas H.F., Yarnell J.W., et al. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am. J. Epidemiol. 145:1997;416-421.
49. Prentice R.L., Szatrowski T.P., Fujikura T., et al. Leukocyte counts and coronary heart disease in a Japanese cohort. Am. J. Epidemiol. 116:1982;496-509.
50. Ma J., Hennekens C.H., Ridker P.M., Stampfer M.J. A prospective study of fibrinogen and risk of myocardial infarction in the Physician's Health Study. J. Am. Coll. Cardiol. 33:1999;1347-1352.
51. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., et al. Fibrinogen as a risk factor for stroke and myocardial infarction. New Engl. J. Med. 311:1984;501-505.
52. Sweetnam P.M., Thomas H.D., Yarnell J.W., et al. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur. Heart J. 17:1996;1814-1820.
53. Kannel W.B., D'Agostino R.B., Belanger A.J. Update on fibrinogen as a cardiovascular risk factor. Ann. Epidemiol. 2:1992;457-466.
54. Meade T.W., Ruddock V., Stirling Y., et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
55. Junker R., Heinrich J., Schulte H., et al. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler. Thromb. Vasc. Biol. 17:1997;1539-1544.
56. Tunstall-Pedoe H., Woodward M., Tavendale R., et al. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. Br. Med. J. 315:1997;722-729.
57. Lowe G.D., Lee A.J., Rumley A., et al. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br. J. Haematol. 96:1997;168-173.
58. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772.
59. Ridker P.M., Hennekens C.H., Roitman-Johnson B., et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 351:1998;88-92.
60. Langer R.D., Criqui M.H., Feigelson H.S., et al. IgE predicts future nonfatal myocardial infarction in men. J. Clin. Epidemiol. 49:1996;203-209.
61. Kovanen P.T., Manttari M., Palosuo T., et al. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch. Intern. Med. 158:1998;1434-1439.
62. Muscari A., Bozzoli C., Puddu G.M., et al. Association of serum C3 levels with the risk of myocardial infarction. Am. J. Med. 98:1995;357-364.
63. Keshavamurthy C.B., Kane G.R., Magdum A.P., Sahoo P.K. Serum fibrinogen and C-reactive protein levels predict major adverse cardiac events in unstable angina. Indian Heart J. 52:2000;36-39.
64. Heeschen C., Hamm C.W., Bruemmer J., Simoons M.L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis, CAPTURE Investigators. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial. J. Am. Coll. Cardiol. 35:2000;1535-1542.
65. Soeki T., Tamura Y., Shinohara H., et al. Fibrinolytic factors, serum lipid and C-reactive protein predicting cardiac events in Japanese patients with coronary atherosclerotic lesions. Jpn. Circ. J. 63:1999;976-980.
66. Lee W.H., Lee Y., Kim J.R., et al. Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina pectoris. Exp. Mol. Med. 31:1999;159-164.
67. de Winter R.J., Bholasingh R., Lijmer J.G., et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc. Res. 42:1999;240-245.
68. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 99:1999;855-860.
69. Rebuzzi A.G., Quaranta G., Liuzzo G., et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am. J. Cardiol. 82:1998;715-719.
70. Ridker P.M., Rifai N., Pfeffer M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 98:1998;839-844.
71. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. J. Am. Coll. Cardiol. 31:1998;1460-1465.
72. Anzai T., Yoshikawa T., Shiraki H., et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 96:1997;778-784.
73. Haverkate F., Thompson S.G., Pyke S.D., et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet. 349:1997;462-466.
74. Pietila K.O., Harmoinen A.P., Jokiniitty J., Pasternack A.I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur. Heart J. 17:1996;1345-1349.
75. Thompson S.G., Kienast J., Pyke S.D., et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. New Engl. J. Med. 332:1995;635-641.
76. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New Engl. J. Med. 331:1994;417-424.
77. Ferreiros E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 100:1999;1958-1963.
78. Tommasi S., Carluccio E., Bentivoglio M., et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am. J. Cardiol. 83:1999;1595-1599.
79. Nikfardjam M., Mullner M., Schreiber W., et al. The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J. Intern. Med. 247:2000;341-345.
80. Gheno G., Libardoni M., Zeppellini R., Cucchini F. C-reactive protein on admission as a predictor of in-hospital death in the elderly with acute myocardial infarction. Cardiologia. 44:1999;1023-1028.
81. Kugiyama K., Ota Y., Kawano H., et al. Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina. Cardiovasc. Res. 47:2000;159-165.
82. Pellegatta F., Pizzetti G., Lu Y., et al. Soluble E-selectin and intracellular molecule-1 plasma levels increase during acute myocardial infarction. J. Cardiovasc. Pharmacol. 30:1997;455-460.
83. Toss H., Lindahl B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation. 96:1997;4204-4210.
84. Schlant R.C., Forman S., Stamler J., Canner P.L. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project. Circulation. 66:1982;401-414.
85. Lowe G.D., Machado S.G., Krol W.F., et al. White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb. Haemost. 54:1985;700-703.
86. Haines A.P., Howarth D., North W.R., et al. Haemostatic variables and the outcome of myocardial infarction. Thromb. Haemost. 50:1983;800-803.
87. Amaro A, Gonzales-Juanatey JR, Iglesias C, et al. Leukocyte count as predictor of the severity ischaemic heart disease as evaluated by coronary angiography, Rev. Port. Cardiol. 1993;12:913-7, 899.
88. Verheggen P.W., de Maat M.P., Cats V.M., et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur. Heart J. 20:1999;567-574.
89. Thompson S.G., Fechtrup C., Squire E., et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler. Thromb. Vasc. Biol. 16:1996;357-362.
90. Fuchs J., Pinhas A., Davidson E., et al. Plasma viscosity, fibrinogen and haematocrit in the course of unstable angina. Eur. Heart J. 11:1990;1029-1032.
91. Benderly M., Graff E., Reicher-Reiss H., et al. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler. Thromb. Vasc. Biol. 16:1996;351-356.
92. Benamer H., Steg P.G., Benessiano J., et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am. J. Cardiol. 82:1998;845-850.
93. Montalescot G., Philippe F., Ankri A., et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French investigators of the ESSENCE trial. Circulation. 98:1998;294-299.
94. Oltrona L., Ardissino D., Merlini P.A., et al. C-reactive protein elevation and early outcome in patients with unstable angina pectoris. Am. J. Cardiol. 80:1997;1002-1006.
95. Biasucci L.M., Liuzzo G., Fantuzzi G., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 99:1999;2079-2084.
96. Ridker P.M., Rifai N., Pfeffer M., et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 101:2000;2149-2153.
97. Zeitler H., Ko Y., Zimmermann C., et al. Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction. Eur. J. Med. Res. 2:1997;389-394.
98. Wallen N.H., Held C., Rehnqvist N., Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur. Heart J. 20:1999;1039-1043.
99. Gurfinkel E.P., Scirica B.M., Bozovich G., et al. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am. J. Cardiol. 83:1999;515-518.
100. Morrow D.A., Rifai N., Antman E.M., et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J. Am. Coll. Cardiol. 35:2000;358-362.
101. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J. Am. Med. Assoc. 279:1998;1477-1482.
102. Kaftan A.H., Kaftan O. Coronary artery disease and infection with Chlamydia pneumonia. Jpn. Heart J. 41:2000;165-172.
103. Zhu J., Quyyumi A.A., Norman J.E., et al. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J. Am. Coll. Cardiol. 34:1999;1738-1743.
104. Rifai N., Joubran R., Yu H., et al. Inflammatory markers in men with angiographically documented coronary heart disease. Clin. Chem. 45:1999;1967-1973.
105. Erren M., Reinecke H., Junker R., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler. Thromb. Vasc. Biol. 19:1999;2355-2363.
106. Kaftan H.A., Kaftan O., Kilic M. Markers of chronic infection and inflammation. Are they important in cases with chronic coronary heart diseases. Jpn. Heart J. 40:1999;275-280.
107. Abdelmouttaleb I., Danchin N., Ilardo C., et al. C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am. Heart J. 137:1999;346-351.
108. Anderson J.L., Carlquist J.F., Muhlestein J.B., et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J. Am. Coll. Cardiol. 32:1998;35-41.
109. Ikonomidis I., Andreotti F., Economou E., et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 100:1999;793-798.
110. Lee W.H., Lee Y., Kim J.R., et al. Activation of monocytes, T-lymphocytes and plasma inflam markers in angina patients. Exp. Mol. Med. 31:1999;159-164.
111. Holvoet P., Vanhaecke J., Janssens S., et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 98:1998;1487-1494.
112. Taturo M.C., Heinrich J., Junker R., et al. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur. Heart J. 20:1999;1493-1502.
113. Bauersachs R.M., Moessmer G., Koch G., et al. Flow resistance of individual neutrophils in coronary artery disease: decreased pore transmit times in acute myocardial infarction. Heart. 77:1997;18-23.
114. Dinerman J.L., Mehta J.L., Saldeen T.G., et al. Increased neutrophils elastase release in unstable angina pectoris and acute myocardial infarction. J. Am. Coll. Cardiol. 15:1990;1559-1563.
115. Muscari A., Nanni Costa A., Bozzoli C., et al. Immunologic changes in circulating leukocytes in the presence of atherosclerotic disease. Recenti Prog. Med. 85:1994;166-173.
116. Eriksson M., Egberg N., Wamala S., et al. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler. Thromb. Vasc. Biol. 19:1999;67-72.
117. Abrignani M.G., Novo G., Di Girolamo A., et al. Increased plasma levels of fibrinogen in acute and chronic ischemic coronary syndromes. Cardiologia. 44:1999;1047-1052.
118. Swahn E., von Schenck H., Wallentin L. Plasma fibrinogen in unstable coronary artery disease. Scand. J. Clin. Lab. Invest. 49:1989;49-54.
119. Sato S., Kobayashi T., Iida M., et al. A case-reference study on plasma fibrinogen concentrations and coronary atherosclerosis in Japanese. J. Epidemiol. 6:1996;81-86.
120. Mazzone A., De Servi S., Vezzoli M., et al. Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis. 145:1999;369-374.
121. Simon A.D., Yazdani S., Wang W., et al. Circulating levels of IL-1beta, a prothrombotic cytokine, are elevated in unstable angina versus stable angina. J. Thromb. Thrombolysis. 9:2000;217-222.
122. Hasdai S., Scheinowitz M., Leibovitz E., et al. Increased serum concentrations of interleukin-1 beta in patients with coronary artery disease. Heart. 76:1996;24-28.
123. Kaikita K., Ogawa H., Yasue H., et al. Increased plasma soluble intercellular adhesion molecule-1 levels in patients with acute myocardial infarction. Jpn. Circ. J. 61:1997;741-748.
124. Blann A., McCollum C.N. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb. Haemost. 72:1994;151-154.
125. Haught W.H., Mansour M., Rothlein R., et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am. Heart J. 132:1996;1-8.
126. Galvani M., Ferrini D., Ottani F., et al. Soluble E-selectin is not a marker of unstable coronary plaque in serum of patients with ischemic heart disease. J. Thromb. Thrombolysis. 9:2000;53-60.
127. Criqui M.H., Lee E.R., Hamburger R.N., et al. IgE and cardiovascular disease. Results from a population-based study. Am. J. Med. 82:1987;964-968.
128. Korkmaz M.E., Oto A., Saraclar Y., et al. Levels of IgE in the serum of patients with coronary arterial disease. Int. J. Cardiol. 31:1991;199-204.
129. Muscari A., Bozzoli C., Puddu G.M., et al. Increased serum IgA levels in subjects with previous myocardial infarction or other major ischemic events. Cardiology. 83:1993;383-389.
130. Muscari A., Bozzoli C., Gerranta C., et al. Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis. 74:1988;179-186.
131. Tao M. Study on clinical immunity in patients with coronary artery disease. Blood Press. Suppl. 3:1996;63-64.
132. Muscari A., Massarelli G., Bastagli L., et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur. Heart J. 21:2000;1081-1090.
133. Saku K., Zhang B., Ohta T., et al. Levels of soluble cell adhesion molecules in patients with angiographically defined coronary atherosclerosis. Jpn. Circ. J. 63:1999;19-24.
134. Kassirer M., Zeltser D., Prochorov V., et al. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. Am. Heart J. 138:1999;555-559.
135. Leibovitz E., Hertz Y., Liberman E., et al. Increased adhesiveness of white blood cells in patients with unstable angina: additional evidence for an involvement of the immunoinflammatory system. Clin. Cardiol. 20:1997;1017-1020.
136. Biasucci L.M., D'Onofrio G., Liuzzo G., et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J. Am. Coll. Cardiol. 27:1996;611-616.
137. Leatham E.W., Bath P.M., Tooze J.A., Camm A.J. Increased monocyte tissue factor expression in coronary disease. Br. Heart J. 73:1995;10-13.
138. Tashiro H., Shimokawa H., Yamamoto K., et al. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron. Artery Dis. 8:1997;143-147.
139. Amaro A., Gude F., Gonzalez-Juanatey R., et al. Plasma leukocyte elastase concentration in angiographically diagnosed coronary artery disease. Eur. Heart J. 16:1995;615-622.
140. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32:1998;368-372.
141. Liuzzo G., Buffon A., Biasucci L.M., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 98:1998;2370-2376.
142. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 94:1996;874-877.
143. Berk B.C., Weintraub W.S., Alexander R.W. Elevation of C-reactive protein in 'active' coronary artery disease. Am. J. Cardiol. 65:1990;168-172.
144. Caliguri G., Liuzzo G., Biasucci L.M., Maseri A. Immune system activation follows inflammation in unstable angina: pathogenetic implications. J. Am. Coll. Cardiol. 32:1998;1295-1304.
145. Holvoet P., Collen D., Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. J. Am. Med. Assoc. 281:1999;1718-1721.
146. Jude B., Agraou B., McFadden E.P., et al. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation. 90:1994;1662-1668.
147. Ogawa H., Yasue H., Miyao Y., et al. Plasma soluble intercellular adhesion molecule-1 levels in coronary circulation in patients with unstable angina. Am. J. Cardiol. 83:1999;38-42.
148. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 100:1999;614-620.
149. Neri Serneri G.G., Prisco D., Martini F., et al. Acute T-cell activation is detectable in unstable angina. Circulation. 95:1997;1806-1812.
150. Olt I., Neumann F.S., Gawaz M., et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 94:1996;1239-1246.
151. Garcia-Moll X., Cole D., Zouridakis E., Kaski J.C. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart. 83:2000;346-350.
152. Takeshita S., Isshiki T., Ochiai M., et al. Systemic inflammatory responses in acute coronary syndrome: increased activity observed in polymorphonuclear leukocytes but not T lymphocytes. Atherosclerosis. 135:1997;187-192.
153. Serneri G.G., Abbate E., Gori A.M., et al. Transient intermittent lymphocytes activation is responsible for the instability of angina. Circulation. 86:1992;790-797.
154. Nishiyama K., Ogawa H., Yasue H., et al. Simulataneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn. Circ. J. 62:1998;710-712.
155. Ueda K., Takahashi M., Ozawa K., Kinoshita M. Decreased soluble interleukin-6 receptor in patients with a acute myocardioal infarction. Am. Heart J. 138:1999;908-915.
156. Gussekloo J., Schaap M.C., Frolich M., et al. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler. Thromb. Vasc. Biol. 20:2000;1047-1051.
157. Muir K.W., Weir C.J., Alwan W., et al. C-reactive protein and outcome after ischemic stroke. Stroke. 30:1999;981-985.
158. Beamer N.B., Coull B.M., Clark W.M., et al. Persistent inflammatory response in stroke survivors. Neurology. 50:1998;1722-1728.
159. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. 45:1999;2136-2141.
160. Zhang Y.X., Cliff W.J., Shoefl G.I., Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 145:1999;375-379.
161. Rohde L.E., Lee R.T., Rivero J., et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 18:1998;1765-1770.
162. Saito D., Shiraki T., Oka T., et al. Morphologic correlation between atherosclerotic lesions of the carotid and coronary arteries in patients with angina pectoris. Jpn. Circ. J. 63:1999;522-526.
163. Ford E.S., Giles W.H. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler. Thromb. Vasc. Biol. 20:2000;1052-1056.
164. Elneihoum A.M., Falke P., Axelsson L., et al. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke. 27:1996;1734-1738.
165. Meier C.R., Jick S.S., Derby L.E., et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet. 351:1998;1467-1471.
166. De Servi S., Mazzone A., Ricevuti G., et al. Clinical and angiographic correlates of leukocytes activation in unstable angina. J. Am. Coll. Cardiol. 26:1995;1146-1150.
167. Mazzone A., De Servi S., Ricevuti G., et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation. 88:1993;358-363.
168. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein
169. Sinzinger H., Pirich C. Platelet function and fibrionogen. Ernst E., Koenig E., Lowe G.D.O., Meade T.W. Fibrinogen: a 'new' cardiovascular risk factor. 1992;46-50 Blackwell-MZV, Vienna, Austria.
170. Thompson W.D., Stirk C.M., Smith E.B. Fibrin degradation products as the pathological growth stimulus to atherosclerotic plaque formation. Ernst E., Koenig W., Lowe G.D.O., Meade T.W. Fibrinogen: a 'new' cardiovascular risk factor. 1992;35-40 Blackwell-MZV, Vienna, Austria.
171. Seino Y., Ikeda M., Yamamoto K., et al. Interleukin-gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 6:1994;87-91.
172. Rus H.G., Vlaicu R., Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 127:1996;263-271.
173. O'Brien K.D., Allen M.D., McDonald T.O., et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis. J. Clin. Invest. 92:1993;945-951.
174. Davies M.J., Gordon J.L., Gearing A.J., et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 171:1993;223-229.
175. Cybulsky M.I., Gimbrone M.A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1991;788-791.
176. Li H., Cybulsky M.I., Gimbrone M.A., Libby P. An atherogenic diet rapidly induced VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. 13:1993;197-204.
177. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation. 100:1999;230-235.
178. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 353:1999;983-984.
179. Anderson J.L., Mehlestein J.B. The ACADEMIC study in perspective (azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). J. Infect. Dis. 181:2000;S569-S571.
180. Kleinert S. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart outcomes prevention evaluation. Lancet. 354:1999;841.
181. Kim J.A., Berliner J.A., Nadler J.L. Angiotensin II increases monocyte binding to endothelial cells. Biochem. Biophys. Res. Commun. 226:1996;862-868.
182. Hernandez-Presa M., Bustos C., Ortego M., et al. Angiotensin-converting enzyme prevents arterial nuclear factor kappa-B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95:1997;1532-1541.
183. Strawn W.B., Chappell M.C., Dean R.H., et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 101:2000;1586-1593.